Todd W Miller Selected Research

Estrogen Receptor Modulators (Antiestrogen)

1/2021	High estrogen receptor alpha activation confers resistance to estrogen deprivation and is required for therapeutic response to estrogen in breast cancer.
1/2018	Autophagy promotes escape from phosphatidylinositol 3-kinase inhibition in estrogen receptor-positive breast cancer.
1/2016	Strategically Timing Inhibition of Phosphatidylinositol 3-Kinase to Maximize Therapeutic Index in Estrogen Receptor Alpha-Positive, PIK3CA-Mutant Breast Cancer.
2/2014	Managing breast cancers with low estrogen receptor and HER2 by drugging both.
1/2014	Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways.
1/2013	Endocrine resistance: what do we know?
1/2013	Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation.
10/2012	Discordant cellular response to presurgical letrozole in bilateral synchronous ER+ breast cancers with a KRAS mutation or FGFR1 gene amplification.
7/2012	Membrane-initiated estrogen signaling: oncogenic or impotent?
1/2012	Abrogating endocrine resistance by targeting ERα and PI3K in breast cancer.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Todd W Miller Research Topics

Disease

47	Neoplasms (Cancer) 01/2021 - 09/2005
39	Breast Neoplasms (Breast Cancer) 01/2021 - 05/2009
4	Disease Progression 08/2020 - 05/2003
4	Huntington Disease (Huntington's Disease) 09/2005 - 05/2003
3	Neurodegenerative Diseases (Neurodegenerative Disease) 09/2005 - 05/2003
2	Urinary Bladder Neoplasms (Bladder Cancer) 01/2021 - 01/2020
2	Triple Negative Breast Neoplasms 11/2020 - 01/2019
2	Lung Neoplasms (Lung Cancer) 08/2020 - 01/2018
2	Neoplasm Metastasis (Metastasis) 01/2017 - 01/2016
1	Pancreatic Neoplasms (Pancreatic Cancer) 01/2021
1	Non-Muscle Invasive Bladder Neoplasms 01/2020
1	Glioblastoma (Glioblastoma Multiforme) 09/2019
1	Ductal Carcinoma 01/2019
1	Adenocarcinoma 01/2019
1	Noninfiltrating Intraductal Carcinoma (DCIS) 01/2019
1	Ovarian Neoplasms (Ovarian Cancer) 01/2019
1	Cardiotoxicity 09/2016
1	Mucinous Adenocarcinoma (Mucinous Carcinoma) 09/2016

Drug/Important Bio-Agent (IBA)

21	Estrogen ReceptorsIBA 01/2019 - 05/2009
17	Estrogens (Estrogen)FDA Link 01/2021 - 07/2010
15	Estrogen Receptor Modulators (Antiestrogen)IBA 01/2021 - 05/2009
13	Pharmaceutical PreparationsIBA 01/2021 - 09/2005
13	Biomarkers (Surrogate Marker)IBA 01/2020 - 05/2003
10	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 01/2018 - 01/2011
9	Hormones (Hormone)IBA 01/2019 - 05/2009
8	Aromatase InhibitorsIBA 01/2021 - 04/2011
7	DNA (Deoxyribonucleic Acid)IBA 08/2020 - 05/2003
7	Proteins (Proteins, Gene)FDA Link 01/2019 - 05/2003
7	Phosphotransferases (Kinase)IBA 01/2018 - 05/2009
6	Fulvestrant (Faslodex)FDA Link 01/2019 - 05/2009
5	Estrogen Receptor alphaIBA 01/2021 - 01/2014
3	Letrozole (Femara)FDA LinkGeneric 02/2018 - 04/2011
3	Mechanistic Target of Rapamycin Complex 1IBA 02/2018 - 03/2017
3	Phosphoric Monoester Hydrolases (Phosphatases)IBA 01/2014 - 05/2009
3	Tyrosine Kinase InhibitorsIBA 11/2011 - 05/2009
3	Tamoxifen FDA LinkGeneric 11/2011 - 05/2009
2	LipidsIBA 01/2020 - 01/2014
2	Dietary Fats (Dietary Fat)IBA 01/2020 - 01/2020
2	exemestane (Aromasin)FDA Link 02/2018 - 09/2016
2	3- (8- amino- 1- (2- phenylquinolin- 7- yl)imidazo(1,5- a)pyrazin- 3- yl)- 1- methylcyclobutanolIBA 02/2018 - 11/2011
2	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2018 - 05/2009
2	2- (1H- indazol- 4- yl)- 6- (4- methanesulfonylpiperazin- 1- ylmethyl)- 4- morpholin- 4- ylthieno(3,2- d)pyrimidineIBA 01/2018 - 01/2016
2	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 03/2017 - 10/2013
2	LigandsIBA 11/2016 - 01/2012
2	Progesterone Receptors (Progesterone Receptor)IBA 01/2014 - 01/2014
2	TensinsIBA 01/2014 - 05/2009
2	Insulin-Like Growth Factor I (IGF-1)IBA 01/2013 - 11/2011
2	Small Interfering RNA (siRNA)IBA 10/2012 - 05/2009
2	IGF Type 1 Receptor (IGF 1 Receptor)IBA 11/2011 - 05/2009
2	Trastuzumab (Herceptin)FDA Link 12/2009 - 07/2009
2	Annexin A5IBA 12/2009 - 07/2009
2	polyglutamineIBA 08/2005 - 06/2005
2	Single-Chain AntibodiesIBA 08/2005 - 06/2005
1	Cisplatin (Platino)FDA LinkGeneric 01/2021
1	Gemcitabine FDA Link 01/2021
1	B7-H1 AntigenIBA 11/2020
1	130-nm albumin-bound paclitaxelIBA 11/2020
1	Circulating Tumor DNAIBA 08/2020
1	MicroRNAs (MicroRNA)IBA 01/2020
1	Fatty Acids (Saturated Fatty Acids)IBA 01/2020
1	Protein Kinases (Protein Kinase)IBA 01/2020
1	VLDL LipoproteinsIBA 01/2020
1	Metformin (Glucophage)FDA LinkGeneric 01/2020
1	Adenosine Monophosphate (AMP)IBA 01/2020
1	Retinoblastoma ProteinIBA 09/2019
1	Cyclin-Dependent Kinases (cdk Proteins)IBA 09/2019
1	ribociclibIBA 09/2019
1	RNA (Ribonucleic Acid)IBA 01/2019
1	Biological ProductsIBA 01/2019
1	Messenger RNA (mRNA)IBA 01/2019
1	palbociclibIBA 01/2019
1	CytokinesIBA 01/2019
1	Everolimus FDA Link 02/2018
1	Chloroquine (Aralen)FDA LinkGeneric 01/2018
1	Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor)IBA 01/2018
1	Antimalarials (Antimalarial Agents)IBA 01/2018
1	AlpelisibIBA 06/2017
1	GSK2636771IBA 06/2017
1	Cytotoxins (Cytolysins)IBA 06/2017
1	Growth Factor ReceptorsIBA 06/2017
1	Protein Isoforms (Isoforms)IBA 06/2017
1	Therapeutic UsesIBA 06/2017
1	Cytostatic AgentsIBA 06/2017
1	70-kDa Ribosomal Protein S6 Kinases (Ribosomal Protein S6 Kinases, 70 kDa)IBA 03/2017
1	PF-4708671IBA 03/2017
1	GTP Phosphohydrolases (GTPases)IBA 03/2017
1	EHT 1864IBA 03/2017
1	Histone Deacetylases (Histone Deacetylase)IBA 11/2016
1	Doxorubicin (Adriamycin)FDA LinkGeneric 09/2016
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 09/2016
1	Paclitaxel (Taxol)FDA LinkGeneric 09/2016
1	Goserelin (Zoladex)FDA Link 09/2016
1	AnthracyclinesIBA 09/2016
1	Formaldehyde (Formol)FDA Link 01/2016

Therapy/Procedure

31	Therapeutics 01/2021 - 09/2005
6	Drug Therapy (Chemotherapy) 01/2021 - 07/2012
3	Neoadjuvant Therapy 11/2020 - 04/2011
2	Immunotherapy 11/2020 - 08/2020
1	Precision Medicine 01/2019
1	Radiotherapy 01/2019